SQLite Web: event_store.db

Update row 1017 in events

seq

Primary key. INTEGER

id

TEXT NOT NULL

kind

TEXT NOT NULL

ts

TEXT NOT NULL

actor

TEXT

subject_entity_ids

TEXT

payload

{"created_at":"2026-04-07T23:23:54.391414+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:3504494e43338995","evidence_event_ids":["evt_d01421be6b51"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001950047-26-003230.txt","as_of":"2026-04-07T23:23:54.391414+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001950047-26-003230.txt","company":"Travere Therapeutics, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001950047-26-003230.txt","article_chars":1756,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_3fcc77a692a443cd","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001950047-26-003230.txt","content_type":"text/plain","enriched_at":"2026-04-07T23:39:40.921759+00:00","extraction_method":"heuristic","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001950047-26-003230.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001950047-26-003230.txt","source_event_id":"evt_d01421be6b51","source_quality":"medium","status_code":200,"version":"signal_enrichment_v2"},"form_type":"144","fp":"44d3be14fe614755","kind":"sec_filing","published_at":"20260406","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.72,"dates_mentioned":["2026-04-06","2026-04-07T23:23:54.391414+00:00","11/17/2025","20130220","20080625"],"entities":[{"asset_class":"equity","name":"Travere Therapeutics, Inc.","relevance":"high","symbol":"TVTX","type":"issuer"},{"asset_class":"equity","name":"Roy D. Baynes","relevance":"high","symbol":"","type":"reporting_owner"},{"asset_class":"equity","name":"Morgan Stanley Smith Barney LLC","relevance":"medium","symbol":"","type":"broker"}],"event_type":"listing","information_gaps":["No prior known state is provided, so the \u201cwhat changed vs prior\u201d portion cannot be determined from this signal alone.","The filing\u2019s specific Form 144 table fields (e.g., exact number of shares disposed, aggregate market value, relationship to issuer, and whether it is a sale vs transfer) are not fully interpretable from the truncated/cleaned text provided.","The meaning of \u201c92241550\u201d and the \u201c10000\u201d fields is not explicitly labeled in the provided excerpt.","No explicit TVTX ticker appears in the provided text; the symbol is inferred only from the signal headline (\u201cTVTX\u201d) and is not directly present in the filing excerpt."],"key_facts":["SEC accession number: 0001950047-26-003230.","Conformed submission type: Form 144.","Filed as of date and date as of change: 2026-04-06.","Subject company: Travere Therapeutics, Inc. (CIK 0001438533).","Reporting owner: Roy D. Baynes (Director).","The filing includes a transaction labeled \u201cStock Option Exercise\u201d with \u201cCash\u201d marked as \u201cY\u201d.","A numeric value shown in the filing: 330000.00 (context not fully specified in provided text).","A date shown for the transaction: 11/17/2025.","Exchange/market and class shown: \u201cNASDAQ Common\u201d.","Signature line shows /s/ Roy Dennis Baynes and date 04/06/2026."],"numeric_claims":[{"label":"Transaction date (as shown)","value":"11/17/2025"},{"label":"Filed as of date","value":"2026-04-06"},{"label":"Value shown","value":"330000.00"},{"label":"Quantity/shares shown (if applicable)","value":"10000"},{"label":"Price/shares-related number shown (if applicable)","value":"92241550"}],"primary_claim":"On 2026-04-06, Travere Therapeutics, Inc. filed SEC Form 144 (accession 0001950047-26-003230) disclosing a common stock transaction by Roy D. Baynes.","relevance_score":0.45,"sentiment":"neutral","source_quality":"medium","summary":"Travere Therapeutics, Inc. filed a Form 144 on 2026-04-06. The filing indicates a reported transaction related to common stock, including an option exercise and cash consideration, by reporting owner Roy D. Baynes (Director).","topics":["SEC Form 144","insider sale/transfer disclosure","common stock","option exercise","reporting owner","Travere Therapeutics"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 144 \u00b7 Travere Therapeutics, Inc. \u00b7 Filed 20260406","ticker":"TVTX","tickers":["TVTX"],"title":"TVTX filed 144","url":"https://www.sec.gov/Archives/edgar/data/1438533/0001950047-26-003230.txt"}}

TEXT NOT NULL

source_ref

TEXT

confidence

REAL (default 0.0

dedupe_key

TEXT

episode_id

TEXT

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

Cancel